$1.92
-0.01-0.52%
At close: -
$1.92
0.000.00%
After Hours: 4:00 PM EDT
Comments
Loading...
Heron Therapeutics Analyst Ratings and Price Targets | NASDAQ:HRTX | Benzinga
Heron Therapeutics Inc has a consensus price target of $6.75 based on the ratings of 4 analysts. The high is $10 issued by Evercore ISI Group on March 24, 2023. The low is $4 issued by Needham on April 11, 2025. The 3 most-recent analyst ratings were released by Needham on April 11, 2025, February 28, 2025, and December 4, 2024, respectively. With an average price target of $4 between Needham, there's an implied 108.33% upside for Heron Therapeutics Inc from these most-recent analyst ratings.
Analyst Firms Making Recommendations1
Needham
Rodman & Renshaw
Capital One
Evercore ISI Group
1calculated from analyst ratings
Analyst Ratings for Heron Therapeutics
| Buy Now | Get Alert | |||||||
|---|---|---|---|---|---|---|---|---|
| 04/11/2025 | Buy Now | 108.33% | Needham | Serge Belanger62% | $4 → $4 | Reiterates | Buy → Buy | Get Alert |
| 02/28/2025 | Buy Now | 108.33% | Needham | Serge Belanger62% | $4 → $4 | Reiterates | Buy → Buy | Get Alert |
| 12/04/2024 | Buy Now | 108.33% | Needham | Serge Belanger62% | $4 → $4 | Reiterates | Buy → Buy | Get Alert |
| 11/13/2024 | Buy Now | 108.33% | Needham | Serge Belanger62% | $5 → $4 | Maintains | Buy | Get Alert |
| 09/25/2024 | Buy Now | 160.42% | Needham | Serge Belanger62% | $5 → $5 | Reiterates | Buy → Buy | Get Alert |
| 08/07/2024 | Buy Now | 160.42% | Needham | Serge Belanger62% | $5 → $5 | Reiterates | Buy → Buy | Get Alert |
| 06/13/2024 | Buy Now | 264.58% | Rodman & Renshaw | Brandon Folkes39% | → $7 | Initiates | → Buy | Get Alert |
| 05/16/2024 | Buy Now | 160.42% | Needham | Serge Belanger62% | $5 → $5 | Reiterates | Buy → Buy | Get Alert |
| 05/08/2024 | Buy Now | 160.42% | Needham | Serge Belanger62% | $5 → $5 | Reiterates | Buy → Buy | Get Alert |
| 04/23/2024 | Buy Now | 212.5% | Capital One | Tim Chiang38% | → $6 | Initiates | → Overweight | Get Alert |
| 04/11/2024 | Buy Now | 160.42% | Needham | Serge Belanger62% | $5 → $5 | Reiterates | Buy → Buy | Get Alert |
| 03/13/2024 | Buy Now | 160.42% | Needham | Serge Belanger62% | $4 → $5 | Maintains | Buy | Get Alert |
| 11/15/2023 | Buy Now | 108.33% | Needham | Serge Belanger62% | $5 → $4 | Maintains | Buy | Get Alert |
| 08/15/2023 | Buy Now | 160.42% | Needham | Serge Belanger62% | → $5 | Reiterates | Buy → Buy | Get Alert |
| 07/25/2023 | Buy Now | 160.42% | Needham | Serge Belanger62% | $6 → $5 | Maintains | Buy | Get Alert |
| 05/12/2023 | Buy Now | 212.5% | Needham | Serge Belanger62% | $7 → $6 | Maintains | Buy | Get Alert |
| 04/21/2023 | Buy Now | 264.58% | Needham | Serge Belanger62% | → $7 | Reiterates | → Buy | Get Alert |
| 03/24/2023 | Buy Now | 420.83% | Evercore ISI Group | Shweta Khajuria50% | $15 → $10 | Maintains | Outperform | Get Alert |
| 03/24/2023 | Buy Now | 264.58% | Needham | Serge Belanger62% | $8 → $7 | Maintains | Buy | Get Alert |
| 11/09/2022 | Buy Now | 316.67% | Needham | Serge Belanger62% | $10 → $8 | Maintains | Buy | Get Alert |
| 06/30/2022 | Buy Now | 420.83% | Needham | Serge Belanger62% | $14 → $10 | Maintains | Buy | Get Alert |
| 05/10/2022 | Buy Now | 629.17% | Needham | Serge Belanger62% | $16 → $14 | Maintains | Buy | Get Alert |
FAQ
What is the target price for Heron Therapeutics (HRTX) stock?
The latest price target for Heron Therapeutics (NASDAQ:HRTX) was reported by Needham on April 11, 2025. The analyst firm set a price target for $4.00 expecting HRTX to rise to within 12 months (a possible 108.33% upside). 10 analyst firms have reported ratings in the last year.
What is the most recent analyst rating for Heron Therapeutics (HRTX)?
The latest analyst rating for Heron Therapeutics (NASDAQ:HRTX) was provided by Needham, and Heron Therapeutics reiterated their buy rating.
When was the last upgrade for Heron Therapeutics (HRTX)?
There is no last upgrade for Heron Therapeutics
When was the last downgrade for Heron Therapeutics (HRTX)?
There is no last downgrade for Heron Therapeutics.
When is the next analyst rating going to be posted or updated for Heron Therapeutics (HRTX)?
Analysts arrive at stock ratings after doing extensive research, which includes going through public financial statements, talking to executives and customers of Heron Therapeutics, and listening in to earnings conference calls. Most analysts do this every three months, so you should get 4 ratings per company per firm each year. The last rating for Heron Therapeutics was filed on April 11, 2025 so you should expect the next rating to be made available sometime around April 11, 2026.
Is the Analyst Rating Heron Therapeutics (HRTX) correct?
While ratings are subjective and will change, the latest Heron Therapeutics (HRTX) rating was a reiterated with a price target of $4.00 to $4.00. The current price Heron Therapeutics (HRTX) is trading at is $1.92, which is out of the analyst’s predicted range.
Browse analyst ratings and price targets on all stocks.